Recently, EPO was found to have new pharmacological activity; for example, it can reduce the incidence rate of BPD in premature infants, especially in the first 4 weeks [26], and it can stimulate the differentiation and proliferation of erythroid progenitor cells [27]. The gene discussed is EPO; the disease is bronchopulmonary dysplasia.